Therapeutic drug monitoring of free perampanel concentrations in practice: A practical analytical technique based on centrifugal ultrafiltration sample separation.

Centrifugal ultrafiltration Children Free drug concentration HPLC-MS/MS Perampanel Therapeutic drug monitoring

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Aug 2024
Historique:
received: 28 04 2024
revised: 16 07 2024
accepted: 02 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

The centrifugal ultrafiltration-high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was established to determine the free perampanel (PER) concentration in children with epilepsy. Free PER concentration was obtained using centrifugal ultrafiltration devices. The internal standard was PER-D5. The method was investigated for selectivity, carryover, lower limit of quantification, calibration curve, accuracy, precision, matrix effects, recovery, and stability. The Spearman's correlation coefficient was used to evaluate the correlation between the free and total PER concentrations. A nonparametric test was used to estimate the effects of PER along with other antiepileptic drugs on the total and free PER concentrations. The free PER concentration was positively correlated with the total PER concentration in the 57 plasma samples ( The proposed method is efficient, sensitive, and suitable for detecting free PER concentrations in children with epilepsy. Simultaneously, the free PER concentration response to clinical outcomes in children with epilepsy was more clinically significant, particularly when combined with VPA.

Identifiants

pubmed: 39170259
doi: 10.1016/j.heliyon.2024.e35734
pii: S2405-8440(24)11765-3
pmc: PMC11336813
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e35734

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ying-Hua Ma (YH)

Department of Pharmacy, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.

Lei Dong (L)

Department of Pharmacy, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.
College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, 050017, PR China.

Jia-Xuan Wu (JX)

College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, 050017, PR China.

Shi-Yuan Hu (SY)

College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, 050017, PR China.

Xiang-Fei Meng (XF)

College of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, 050017, PR China.

Yi-Le Zhao (YL)

Department of Pharmacy, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.

Kang Liu (K)

Department of Neurology, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.
The Key Laboratory of Pediatric Epilepsy and Neuropathy of Hebei Province, Shijiazhuang, PR China.

Dan-Ni Yan (DN)

Department of Neurology, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.
The Key Laboratory of Pediatric Epilepsy and Neuropathy of Hebei Province, Shijiazhuang, PR China.

Su-Zhen Sun (SZ)

Department of Neurology, Children's Hospital of Hebei Province, Shijiazhuang, 050031, PR China.
The Key Laboratory of Pediatric Epilepsy and Neuropathy of Hebei Province, Shijiazhuang, PR China.

Classifications MeSH